{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.8","upperLimit":"64.5","value":"59.8"},{"groupId":"OG001","lowerLimit":"31.4","upperLimit":"45.2","value":"38.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"Clinical benefit was defined as achieving stable disease (SD) or non-complete response (CR)/non-progressive disease (PD) for at least 6 months or a best overall response of confirmed CR or confirmed partial response (PR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"NUMBER","populationDescription":"ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.","reportingStatus":"POSTED","timeFrame":"34.6 months","title":"Clinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}